The estimated Net Worth of Mark Trudeau is at least $15.6 Milion dollars as of 29 April 2024. Mr. Trudeau owns over 7,044 units of Mallinckrodt Plc stock worth over $2,012 and over the last 11 years he sold MNK stock worth over $996,656. In addition, he makes $14,610,800 as President, Chief Executive Officer a Director at Mallinckrodt Plc.
Mark has made over 19 trades of the Mallinckrodt Plc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 7,044 units of MNK stock worth $996,656 on 29 April 2024.
The largest trade he's ever made was exercising 37,341 units of Mallinckrodt Plc stock on 26 December 2013 worth over $1,488,786. On average, Mark trades about 2,901 units every 77 days since 2013. As of 29 April 2024 he still owns at least 5,917 units of Mallinckrodt Plc stock.
You can see the complete history of Mr. Trudeau stock trades at the bottom of the page.
Mark C. Trudeau is President, Chief Executive Officer, Director of Mallinckrodt Public Limited Company. In anticipation of our spin transaction with Covidien plc, Mr. Trudeau joined Covidien in February 2012 as a Senior Vice President and President of its Pharmaceuticals business. He joined Covidien from Bayer HealthCare Pharmaceuticals LLC USA, the U.S. healthcare business of Bayer AG, where he served as Chief Executive Officer. He simultaneously served as President of Bayer HealthCare Pharmaceuticals, the U.S. organization of Bayer’s global pharmaceuticals business. In addition, he served as Interim President of the global specialty medicine business unit from January to August 2010. Prior to joining Bayer in 2009, Mr. Trudeau headed the Immunoscience Division at Bristol-Myers Squibb. During his 10-plus years at Bristol-Myers Squibb, he served in multiple senior roles, including President of the Asia/Pacific region, President and General Manager of Canada and General Manager/Managing Director in the United Kingdom. Mr. Trudeau was also with Abbott Laboratories, serving in a variety of executive positions, from 1988 to 1998. Mr. Trudeau has served as a director of TE Connectivity Ltd. since March 2016. Mr. Trudeau is familiar with all aspects of our business and has extensive and diverse industry experience and managerial expertise and a proven record of leadership to serve as our President, CEO and director.
As the President, Chief Executive Officer a Director of Mallinckrodt Plc, the total compensation of Mark Trudeau at Mallinckrodt Plc is $14,610,800. There are no executives at Mallinckrodt Plc getting paid more.
Mark Trudeau is 58, he's been the President, Chief Executive Officer a Director of Mallinckrodt Plc since 2013. There are 8 older and 5 younger executives at Mallinckrodt Plc. The oldest executive at Mallinckrodt Plc is J. Martin Carroll, 70, who is the Independent Director.
Mark's mailing address filed with the SEC is 1050 WESTLAKES DRIVE, , BERWYN, PA, 19312.
Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P.... a Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Mallinckrodt Plc executives and other stock owners filed with the SEC include: